Global Targeted Drug Delivery Partnering Deals Analysis 2010-2015

Sep 23, 2015, 10:10 ET from Research and Markets

DUBLIN, Sept. 23, 2015 /PRNewswire/ -- Research and Markets ( has announced the addition of the "Global Targeted Drug Delivery Partnering 2010-2015" report to their offering.

Targeted Drug Delivery Partnering 2010-2015 provides understanding and access to the targeted drug delivery partnering deals and agreements entered into by the world's leading healthcare companies.

The report provides a detailed understanding and analysis of how and why companies enter targeted drug delivery partnering deals. The majority of deals are discovery or development stage whereby the licensee obtains a right or an option right to license the licensors drug delivery technology. These deals tend to be multi-component, starting with collaborative R&D, and commercialization of outcomes.

Understanding the flexibility of a prospective partner's negotiated deals terms provides critical insight into the negotiation process in terms of what you can expect to achieve during the negotiation of terms. Whilst many smaller companies will be seeking details of the payments clauses, the devil is in the detail in terms of how payments are triggered - contract documents provide this insight where press releases do not.

Report scope

Targeted Drug Delivery Partnering 2010-2015 is intended to provide the reader with an in-depth understanding and access to targeted drug delivery trends and structure of deals entered into by leading companies worldwide.

This data driven report includes:

  • Trends in targeted drug delivery dealmaking in the biopharma industry since 2010
  • Access to summary headline, upfront, milestone and royalty data
  • Access to over 150 targeted drug delivery actual deal records
  • The leading targeted deals by value since 2010

In Targeted Drug Delivery Partnering 2010-2015, the available deals are listed by:

  • Headline value
  • Upfront payment value
  • Royalty rate value
  • Company A-Z
  • Industry sector
  • Stage of development at signing
  • Deal component type
  • Therapy type

Key Topics Covered:

Executive Summary

Chapter 1 - Introduction

Chapter 2 - Trends in targeted drug delivery dealmaking

Chapter 3 - Average financial deal terms for targeted drug delivery partnering

Chapter 4 - Leading targeted drug delivery deals

Chapter 5 - Targeted drug delivery partnering dealmaking directory

For more information visit

Media Contact:

Laura Wood, +353-1-481-1716,


SOURCE Research and Markets